Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma-Reference-Cited by-同舟云学术

Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma

Published:2017-08-18 Issue:23 Volume:123 Page:4640-4647
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Samuels Brian L.¹^ORCID,Chawla Sant P.²,Somaiah Neeta³^ORCID,Staddon Arthur P.⁴,Skubitz Keith M.⁵^ORCID,Milhem Mohammed M.⁶,Kaiser Pamela E.⁷,Portnoy David C.⁸,Priebat Dennis A.⁹,Walker Mark S.¹⁰,Stepanski Edward J.¹⁰

Affiliation:

1. Summit Cancer Centers; Post Falls Idaho

2. Sarcoma Oncology Center; Santa Monica California

3. Sarcoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston Texas

4. Medical Oncology; University of Pennsylvania; Philadelphia Pennsylvania

5. Department of Medicine; University of Minnesota; Minneapolis Minnesota

6. Medical Oncology; University of Iowa; Iowa City Iowa

7. Oncology Specialists; Park Ridge Illinois

8. West Cancer Center; Memphis Tennessee

9. Department of Medical Oncology; Medstar Washington Hospital Center; Washington District of Columbia

10. Vector Oncology; Memphis Tennessee

Funder

GlaxoSmithKline

Novartis

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.30926/fullpdf

Reference24 articles.

1. Liposarcoma: molecular targets and therapeutic implications;Bill;Cell Mol Life Sci.,2016

2. Liposarcoma: molecular genetics and therapeutics [serial online];Conyers;Sarcoma,2011

3. Sarcoma classification: an update based on the 2013 World Health Organization classification of tumors of soft tissue and bone;Doyle;Cancer.,2014

4. Contemporary therapy for advanced soft-tissue sarcomas in adults: a review;Pang;JAMA Oncol.,2016

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular characteristics and systemic treatment options of liposarcoma: A systematic review;Biomedicine & Pharmacotherapy;2024-09

2. Combination of eribulin and anlotinib exerts synergistic cytotoxicity in retroperitoneal liposarcoma by inducing endoplasmic reticulum stress;Cell Death Discovery;2024-08-08

3. Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms;Cancer Treatment Reviews;2024-04

4. Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection;Cancers;2024-01-08

5. The pyroptosis-related signature predicts prognosis and influences the tumor immune microenvironment in dedifferentiated liposarcoma;Open Medicine;2024-01-01